AgingResearch.NewsJoin free

Dong Wha Pharmaceutical

CompanySouth KoreaFounded 1897

ROR

Dong Wha Pharmaceutical develops 3 assets, the furthest in phase 1 (DW1029M in dw6014). Mostly small molecule and other acting on SLC5A2; based in South Korea, founded in 1897.

3
Assets
Furthest stage
Phase 1
9
Trials
0
Signals

Pipeline

3

  • DW1029M

    Phase 1, Other, dw6014

  • DW6013

    Phase 1, Small molecule, dw6014

  • DW6014

    Selective SGLT2 inhibitor blocking renal glucose reabsorption.

    Phase 1, Small molecule, SLC5A2, dw6014

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms3
  • Trials9
  • Similar companies6

Intelligence